Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 1448 clinical trials
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)

This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19/CD22-Dual-STAR-T cells in patients with refractory and relapsed B cell acute leukemia

  • 14 Jun, 2021
  • 1 location
Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia

After complete remission, elderly AML patients cannot tolerate hematopoietic stem cell transplantation and standard-dose consolidation chemotherapy, and the 5-year survival rate is around 10%. Therefore, it is necessary to explore treatment strategy that can support chemotherapy or improve immunity. Umbilical cord blood is rich in hematopoietic stem cells and immune …

  • 01 Sep, 2021
  • 2 locations
Evaluation of Therapeutic Video Games for Pre-school Children With Acute Lymphoblastic Leukemia

The purpose of this study is to evaluate the effectiveness of therapeutic video game.

  • 10 Sep, 2021
  • 1 location
  • 17 Feb, 2021
  • 9 locations
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) (MK-0482-002)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study. Part 1 is a dose escalation which will follow an accelerated titration design (ATD). Part 2 is a dose expansion in the …

  • 19 Jan, 2022
  • 2 locations
Title: Moxetumomab Pasudotox-tdfk (Lumoxiti ) and Rituximab (Rituxan ) for Relapsed Hairy Cell Leukemia

Background Hairy cell leukemia (HCL) is a rare, slow-growing blood cancer in which the bone marrow makes too many of certain white blood cells. The antibody

  • 19 Jan, 2022
  • 1 location
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)

  • 19 Jan, 2022
  • 12 locations
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Background Hairy cell leukemia (HCL) is highly responsive to but not curable by cladribine (CdA). HCL responds to rituximab, which is not yet standard therapy for

  • 24 Jan, 2022
  • 1 location
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

The rationale for combining lenalidomide with rituximab derives from preclinical observations suggesting that lenalidomide may enhance the ADCC (antigen-dependent cellular cytotoxicity) triggered by monoclonal antibodies such as rituximab. Lenalidomide augments NK cytotoxicity by increasing CD56dimCD3 subset, in addition to inducing IL-2 in T cells. These results provide the cellular and …

monoclonal protein
monoclonal antibodies
chronic lymphocytic leukemia
  • 08 Nov, 2020
  • 1 location
Targeted Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation

The study hypothesis is that higher dose intravenous busulfan can be delivered safely to AML patients undergoing autologous transplantation. If this hypothesis is true the investigators plan to examine in a future study whether higher-dose busulfan can improve overall survival following autologous transplantation for AML.

cell transplantation
  • 07 Nov, 2020
  • 1 location